Fig. 3 | Signal Transduction and Targeted Therapy

Fig. 3

From: Acute hemodynamic effects of TPN171H in pulmonary arterial hypertension: a randomized, controlled, phase 2a trial

Fig. 3The alternative text for this image may have been generated using AI.

Percentage change in PVR/SVR from baseline to 24 h. The least-squares mean differences in the percentage change in the PVR/SVR ratio between the TPN171H 5 mg and placebo groups were −20.5% (95% CI, −38.4 to −2.5; p = 0.026) at 2 h, −19.1% (95% CI, −36.3 to −1.9; p = 0.030) at 3 h, and −14.9% (95% CI, −29.6 to −0.3; p = 0.046) at 5 h. *p < 0.05 refers to comparisons between the TPN171H 5 mg and the placebo groups. Analysis of the mixed model repeated-measures method was used, with the change in PVR/SVR ratio (%) from baseline as the dependent variable, with treatment, hours of observation, and treatment-by-hour interaction as fixed effects, and the baseline PVR/SVR ratio as a covariate. PVR pulmonary vascular resistance, SVR systemic vascular resistance

Back to article page